Sj. Clark et al., Hepatitis B vaccination practices in hospital newborn nurseries before andafter changes in vaccination recommendations, ARCH PED AD, 155(8), 2001, pp. 915-920
Background: Routine use of hepatitis B vaccine for low-risk newborns was su
spended on July 7, 1999, because of concern about the potential risk of thi
merosal, a mercury-containing vaccine preservative. Reinstatement of the bi
rth dose was recommended when a thimerosal-free vaccine became available.
Objective: To explore changes in hepatitis B vaccination practices for newb
orns related to the revised recommendations for low-risk infants (in this s
tudy, the terms newborn and infant are used interchangeably).
Design: A telephone survey of a random sample of 1000 US hospitals.
Participants: Nurse managers, nursery directors, and staff nurses of the ne
wborn nurseries.
Main Outcome Measures: Nursery vaccination practices before and after July
7, 1999, and the availability and use of thimerosal-free vaccine.
Results: Interviews were conducted with 773 (87%) of 886 eligible hospitals
. Before July 7,1999, 78% of the hospitals reported vaccination practices t
hat were consistent with recommendations at that time, although only 47% va
ccinated all low-risk infants at birth. After July 7, 1999, almost all hosp
itals discontinued vaccination of low-risk infants, in accordance with the
recommendation change; however, there was a 6-fold increase in the number o
f hospitals that were not vaccinating all high-risk infants. After the intr
oduction of thimerosal-free vaccine, only 39% of the hospitals reported vac
cinating all low-risk infants.
Conclusions: Most hospital nurseries altered their newborn hepatitis B vacc
ination practices consistent with changes in national recommendations. Howe
ver, unintended consequences included the failure of some hospitals to cont
inue vaccinating all high-risk infants and the delay in reintroducing vacci
nation for low-risk newborns after the introduction of a thimerosal-free va
ccine. Assessments of the appropriateness of this country's response to the
threat of thimerosal in vaccines should consider these findings.